Genomic Designs of rAAVs Contribute to Pathological Changes in the Livers and Spleens of Mice
Open Access
- 20 March 2022
- journal article
- research article
- Published by Wiley in Advances in Cell and Gene Therapy
- Vol. 2022, 1-19
Abstract
Recombinant AAV (rAAV) gene therapy is being investigated as an effective therapy for several diseases including hemophilia B. Reports of liver tumor development in certain mouse models due to AAV treatment and genomic integration of the rAAV vector has raised concerns about the long-term safety and efficacy of this gene therapy. To investigate whether rAAV treatment causes cancer, we utilized two mouse models, inbred C57BL/6 and hemophilia B Balb/C mice (HemB), to test if injecting a high dose of various rAAV8 vectors containing or lacking hFIX transgene, a Poly-A sequence, or the CB or TTR promoter triggered liver fibrosis and/or cancer development over the course of the 6.5-month study. We observed no liver tumors in either mouse cohort regardless of rAAV treatment through ultrasound imaging, gross anatomical assessment at sacrifice, and histology. We did, however, detect differences in collagen deposition in C57BL/6 livers and HemB spleens of rAAV-injected mice. Pathology reports of the HemB mice revealed many pathological phenomena, including fibrosis and inflammation in the livers and spleens across different AAV-injected HemB mice. Mice from both cohorts injected with the TTR-hFIX vector demonstrated minimal adverse events. While not tumorigenic, high dose of rAAVs, especially those with incomplete genomes, can influence liver and spleen health negatively that could be problematic for cementing AAVs as a broad therapeutic option in the clinic.Keywords
Funding Information
- NIH-NHLBI (R01HL130871, U54HL142019, T32HL007910)
This publication has 68 references indexed in Scilit:
- High-Frequency Ultrasound Imaging to Evaluate Liver Fibrosis Progression in Rats and Yi Guan Jian Herbal Therapeutic EffectsEvidence-Based Complementary and Alternative Medicine, 2013
- Gene Therapy for Mucopolysaccharidosis Type VI Is Effective in Cats Without Pre-Existing Immunity to AAV8Human Gene Therapy, 2012
- Induction of hepatocellular carcinoma by in vivo gene targetingProceedings of the National Academy of Sciences, 2012
- Native Molecular State of Adeno-Associated Viral Vectors Revealed by Single-Molecule SequencingHuman Gene Therapy, 2012
- Optimizing Promoters for Recombinant Adeno-Associated Virus-Mediated Gene Expression in the Peripheral and Central Nervous System Using Self-Complementary VectorsHuman Gene Therapy, 2011
- High-Frequency Ultrasound Imaging for Longitudinal Evaluation of Non-Alcoholic Fatty Liver Disease Progression in MiceUltrasound in Medicine & Biology, 2011
- Assessing the potential for AAV vector genotoxicity in a murine modelBlood, 2011
- Complete Correction of Hemophilia A with Adeno-Associated Viral Vectors Containing a Full-Size Expression CassetteHuman Gene Therapy, 2008
- Correction of hemophilia as a proof of concept for treatment of monogenic diseases by fetal spleen transplantationProceedings of the National Academy of Sciences, 2006
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005